Advanced Therapies UK 2027
9 March 2027 – 10 March 2027
ExCeL London, London, United Kingdom
The Advanced Therapies Congress is a commercial cell and gene therapy conference and exhibition for leaders of ATMP companies and the senior executives responsible for the technologies and strategies driving the industry. Held over two days at ExCeL London, it features speakers from across the cell and gene therapy value chain, including pharma, biotech and start-up companies, researchers, clinicians, academics, HTAs, payers and regulators, across multiple content tracks alongside an exhibition and start-up zone.
260 sessions · 232 speakers
Organiser (1)
Sponsors (2)
FUJIFILM Biotechnologies · Cytiva
Exhibitors (7)
Green Elephant Biotech · OriGen Biomedical · Fresenius Kabi · Intertek · VectorBuilder Ltd · Octapharma · 3P BIOPHARMACEUTICALS S.L.U.
Speakers (232)
- Raphael Ognar President & CEO, Co-founder, NKILT Therapeutics Inc.
- Lara Campana SVP, Head of Research and Translational Science, Resolution Therapeutics
- Anji Miller Skills Lead, Innovation Hubs for Gene Therapies/Programme Director, Translational Skills, LifeArc
- David Morrow Scientist, EATRIS
- Katie Binley Chief Scientific Officer, ikarovec
- Alessandra Magnani Head of the advanced therapies and immunotherapy platform, Hospital Sant Joan de Déu Barcelona
- Angela Borghouts - de Ruijter Associate Director Market Access, Gilead Sciences
- Carolina Pola CEO, Stab Therapeutics
- Jaap Jan Boelens Chief, Transplantation and Cellular Therapies, Memorial Sloan-Kettering Cancer Center
- Lindsay Davies CSO, NextCell Pharma and CEO, QVance, NextCell Pharma
- Victor Hernandez CSO, Axovia Therapeutics
- Aline Charpentier Science Strategy & Innovation Lead, Wellcome Genome Campus
- Ben Weil Chief Operating Officer & Chief Manufacturing Officer, InmuneBio
- Peter Andersen Chief Research & Development Officer, TREEFROG THERAPEUTICS
- Owen Bain Director/Qualified Person, Cell & Vector Innovation Centre, Royal Free London NHS Foundation Trust
- Diana Hernandez Director of Immune and Advanced Therapies, Anthony Nolan
- Mark Eccleston CEO, ValiRx
- Sven Kili Partner, Saisei Ventures
- Darius Widera Professor of Stem Cell Biology and Research Division Lead, University of Reading
- Leila Abbas Pre Clinical Lead, Rinri Therapeutics
- Prof James Levine President, Fondation Ipsen
- Sarah Leonard CEO, T-Cypher Bio Ltd
- Patrick Hopkinson Independent HTA Expert, Independent HTA Expert
- Ashleigh Furlong Health reporter, Bloomberg News
- Rahul Khetan Venture Associate, UCB Ventures
- Samantha Barber Chief Executive Officer, Gene People
- Alejandro Madrigal, OBE FMedSci Professor of Haematology, UCL Cancer Institute
- Ali Roghanian Professor in Cancer Immunotherapy, University of Southampton
- Andrew Roddam Founder & Principal, Cibola Life Sciences Ltd
- Anne Rosser Professor of Clinical Neurosciences, Cardiff University
- Arsalan Wafi Academic Clinical Lecturer in Vascular Surgery, King's College London
- Ash Toye Professor of Cell Biology, University of Bristol & Co-founder, Scarlet Therapeutics, University of Bristol
- Ashish Patel Reader in Vascular Surgery & Sciences, King's College London / Guy's & St Thomas' NHS Foundation Trust
- Beatriz Duran Consultant Pharmacist and Head of Clinical Trials Pharmacy Service and ATMPs, Manchester University NHS Foundation Trust
- Bernd Giebel Professor, University Hospital Essen
- Christian Hill Board Member, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
- David Peritt Chief Scientific Officer, Lupagen
- Dimitri Kullmann Professor of Neurology, University College London (UCL)
- Elsa Abranches Chief Scientific Officer, ViSync Technologies
- Gaik Sui Kee Director, Vector Development, Orchard therapeutics
- Giorgia Santilli Associate Professor in Gene Therapy, UCL Great Ormond Street Institute of Child Health
- Hugh JM Brady Professor of Immunology, Imperial College London
- Ilves Sanna Head of Pharmacy Clinical Trials & Aseptic Services, The Royal Marsden NHS Foundation Trust
- Jon Amund Kyte Head of Department for Clinical Cancer Research, University of Oslo, Oslo University Hospital
- Jörg Wischhusen Professor, Universitätsklinikum Würzburg
- Katherine Forsey Chief Research Officer, Charcot Marie Tooth Association
- Manal Mohammed Associate Professor, University of Westminster
- Michael Aigner Head of Manufacturing / QP, University Hospital Erlangen
- Miguel Forte CEO, Kiji Therapeutics and Immediate Past President, International Society of Cell and Gene Therapy, Kiji Therapeutics
- Mohamed Awwad Group Leader, Heidelberg University Hospital
- Nicola Ambler Founder, The CGT Circle
- Olivier Gerrit de Jong Assistant Professor, Utrecht University
- Ricardo Baptista Chief Technology Officer, SmartCella
- Salah Mansour Professor of Cellular Immunology, University of Southampton
- Sara Nolbrant Director, Pre-GMP Facility, Lund Stem Cell Center
- Shirley Bartido Principal Consultant, CELLiCONsultant
- Toby Gamlen Head of Manufacturing, Gene Therapy Innovation and Manufacturing Centre, University of Sheffield
- Claudia Andretta Strategic Advisor, Sichem Bio
- Ángel Lucio CEO, Tetraneuron
- Cem Zorlular CEO, Er-Kim Pharmaceuticals
- Christopher Ballas Global Commercial Lead, Custom Cell Products, Cook MyoSite Inc
- Darren Nesbeth Associate Professor, University College London
- David Kuntin CEO, Mesenbio
- Devin Peipert Professor of Health Outcomes Measurement, University of Birmingham
- Dinesh Kundu CEO, East Ocyon Bio Pvt. Ltd.
- Hannah Crocker Advanced Therapies Outcomes Manager, NHS Wales Joint Commissioning Committee (NWJCC)
- Harris Makatsoris Professor of Manufacturing, King's College London
- Jan Spanholtz Chief Scientific Officer, Glycostem Therapeutics
- Laurie Menger Advanced T-cell Therapy group leader, Gustave Roussy/INSERM
- Lilian Hook Director of Cell, Apheresis and Gene Therapies, NHS Blood and Transplant
- Lior Shaltiel Chief Executive Officer, NurExone Biologic
- Manel Juan Immunologist, Hospital Clínic de Barcelona
- Margareth Jorvid Board Chair, Elicera Therapeutics
- Marit Inngjerdingen Professor, University of Oslo
- Mark Lowdell CSO, InmuneBio
- Melita Irving Group Leader, University of Lausanne
- Mike Broeders Advisor, FAST (Future Affordable Sustainable Therapies)
- Parag Kumthekar Lead Gene Therapy Downstream Process Development, UCB
- Pedro Correa de Sampaio CEO, Neobe Therapeutics
- Piotr Trzonkowski CEO, PolTREG
- Rafiq Hasan CEO, Complement Therapeutics
- Simon Briggs Director Advanced Analytics, Orchard Therapeutics Ltd
- Steffen Goletz Professor, Department of Biotechnology and Biomedicine, Danish Technical University
- Tara Sadeghi Chief Operating Officer, Cellenkos Inc.
- Tatyana Matveeva Director of cGMP Operations, Mass General Hospital
- Ulrich Ruemenapp Senior Biotech Program Lead, Bayer AG
- Vlad Seitan Chief Scientific Officer, Laverock Therapeutics
- James Duboff Strategic Partnerships Director, Genomics England
- Gray Kueberuwa Chief Executive Officer, ImmunoKey
- Killian Hanlon CEO, Lir Therapeutics
- Amelia Lane Director Preclinical Development, MeiraGTx
- Dilip Patel SVP Global Pricing and Market Access, Autolus
- Natalie Francis Head of Process Development, King's College London
- Nagy Habib Imperial College London
- Brad Groves Director, NICE Advice, National Institute for Health & Care Excellence (NICE)
- Pedro Borga Global Pricing Director, BioMarin Pharmaceutical Inc.
- Alison Caldwell Manager, CMC Regulatory Affairs, Resolution Therapeutics
- John Bridgeman CSO, ImmunoKey
- Henriette Burghoorn Associate Director, Market Access, Gilead Sciences
- Ilya Yasny Partner, LanceBio Ventures
- Davide Danovi Independent Partner, Hoya Consulting
- John Maher CSO, Leucid Bio
- Marina Tarunina Research Director, Plasticell
- Padraig Donlon Analytical Development Research Scientist, Autolus
- Aleck Jones CEO and Co-Founder, Kindling Bio
- Jonathan Bracey Founder, MVA Society
- Daniel O’Connor Director, Regulatory Policy and Early Access, ABPI
- Kiren Baines-Mortimore CEO & Co-Founder, Valaya bio
- Semra Kitchen Senior Director, Search & Evaluation, R&I, AstraZeneca
- Sheela Upadhyaya Rare Disease Consultant, Rarely Ordinary
- Amanda Jayne Carr Associate Professor, Institute of Ophthalomolgy U.C.L.
- Amina Al-Mossawi Qualified Person, AM Consultancy
- Andrew Joseph Europe Correspondent, STAT
- Anna-Lina Cavallo Director Discovery Cell and Gene Therapy integrated Bioanalysis, AstraZeneca
- Annalisa Del Prete principal pharmacist for ATMP, Sheffield Teaching Hospitals
- Antonio Roldao Head of Cell-based Vaccines Development Lab, IBET
- Catherine Burns BBC Health Correspondent, BBC News
- Claudiu Cozmescu Postdoctoral Researcher, Gissen Lab, University College London
- Dominic Schmidt General Partner, Advent Life Sciences
- Elena Beltrami Senior Investment Manager, Indaco Biotech Fund
- Emma Ungstrup Principal Consultant, E J Consulting
- Finn Willingham Northern Alliance Advanced Therapies Treatment Centre Operations Manager, The Newcastle upon Tyne Hospitals NHS Foundation Trust
- Heather Main Co-Founder, Hoya Consulting
- Ivana Barbaric Professor of Stem Cell Biology, University of Sheffield
- Jean-Philippe Combal Co-Founder & CEO, Vivet Therapeutics
- Marsela Qesari CMC Manager, Fondazione Telethon
- Matthew Cobb Independent Consultant, Hoya Consulting
- Nicola Redfern Director, NJ Redfern Ltd.
- Nisha Shaunak Trust Head of Programmes, Advanced Therapies, Guy's & St Thomas' NHS Foundation Trust
- Pedro Silva Couto Lecturer, University of Bath
- Pilar Redondo Site Head Madrid, Cell Therapy Technology Center, Takeda
- Rachel Abbott Chief Executive Officer, Pan Cancer T
- Randolph Corteling Chief Scientific Officer, ReNeuron
- Sibtain Haider Postdoctoral Researcher, University Hospital Freiburg
- Simon Howell Professor, KCL
- Tamás Laufer Researcher, UCL x Orchard Therapeutics
- Vicki Coutinho Managing Director & Consultant, Geni Consulting
- Vincent van der Wel CEO, Orfenix
- Adelina Dan Senior MSAT Scientist, GTVF, King's College London
- Adrian Westhaus Researcher, Genethon
- Anastasios Karadimitris Professor, Langmuir Chair in Haematology and Consultant Haematologist, Imperial College London
- Andrew Zambanini Head of Innovative Therapies, Innovation Accelerator, MHRA
- Angela Columbano Head Business Development and Partnership, Genethon
- Anna Koptina CEO, Exellerium
- Anna Louisa Weltin Research Fellow, Fraunhofer IPT
- Anna-Kaisa Lehtivarjo VP Quality Assurance, Resolution Therapeutics Ltd
- Anne Black Regional QA Specialist Pharmacist and Qualified Person, NHS Specialist Pharmacy Service
- Bobby Gaspar Chief Executive Officer, Orchard therapeutics
- Brian Bigger Professor of Advanced Therapeutics, University of Edinburgh
- Chaiyong Koaykul Lecturer, Faculty of Medicine, Chulalongkorn University-Excellence Center For Advanced Therapy Medicinal Products
- Chris Shanks Conference Director, Advanced Therapies, Terrapinn
- Christian Chabannon Professor of Medicine in Cell Biology at Aix-Marseille Université. Medical Director & QP, Institut Paoli-Calmettes (IPC)
- Christopher Benwell Assistant Director of Technical Analytics, ikarovec
- Chrysanthi Sitmalidou Senior Scientist, Orchard therapeutics
- Cornelia Kasper Head of Institute for Cell and Tissue Culture Technologies, University Of Natural Resources And Life Sciences Vienna
- Daniel Fowler Research Fellow, UCL
- Fadi Issa Professor of Transplantation, University of Oxford
- Frederick Vonberg Consultant Neurologist, University College London Hospitals NHS Foundation Trust
- Gaurav Bhavsar Technical Director GTVF, Gene Therapy Vector Facility, Kings College London
- George Frodsham Founder & CEO, MediSieve Limited
- George Hall Research Fellow, UCL
- George Pamenter Research Fellow, UCL
- Giulia Leonetti Policy Officer, European Commission
- Giuliana Minani Bertolino Senior MSAT scientist, GTVF King’s College London
- Gonzalo Fernández-Miranda CEO, CureAge Therapeutics
- Hester Chu Research Assistant, Neurodegenerative Diseases, UCL
- Hugh O'Brien Founder, Lir Therapeutics
- Ilaria Villa Chief Executive Officer, Fondazione Telethon
- Jacob George Chief Medical and Scientific Officer, MHRA
- Jan Claas-von Jachmann CEO, PROVIREX Genome Editing Therapies GmbH
- Janet Glassford Expert Quality Assessor, Biologicals Unit, Medicines & Healthcare products Regulatory Agency
- Janine Kirby Professor, University of Sheffield
- Jara Palomero Qualified Person, VHIO - Vall d'Hebron Institute of Oncology
- Jiri Eitler Principal Investigator, Dresden University of Technology
- Jonathan Sumner Associate Principal Scientist, AstraZeneca
- Jose Meseguer Ripolles Head, Translational Digital and Data Science, Resolution Therapeutics
- Josephine Dietrich Staff Scientist, Center for Regenerative Therapies Dresden (CRTD)
- Julio Castano QP of the Advanced Therapies Platform, Sant Joan de Déu Hospital
- Jun Ishihara Associate Professor, Imperial College London
- Kathryn Parsley SVP, Regulatory Affairs and Product Development Executive, Complement Therapeutics
- Kayleigh Thirlwell Sr Director, Resolution Therapeutics
- Keith Wilson Director, South Wales Blood and Marrow Transplant Programme, Cardiff and Vale University Health Board
- Kieran Breen Scientific Advisor, Parkinson's Europe
- Kristian Tryggvason Chief Executive Officer, Alder Therapeutics
- Luke Lindsay-Hill Senior Stem Cell Scientist, MHRA
- Lyn Healy Visiting Scientist, King's College London
- Marc de la Roche Asst. Professor, Dept. of Biochemistry, University of Cambridge
- Marc Martinez-Llordella Founder and VP Biology, Quell Therapeutics
- Marjolein Meinders Co-Founder, Scarlet Therapeutics
- Mark Exley CSO, LIfT Biosciences
- Mark Isalan Professor of Engineering Biology, Imperial College London/ Toggle Therapeutics
- Marta Serafini Associate Professor, School of Medicine and Surgery, University of Milano-Bicocca
- Mo Girach Honorary Fellow, University of Buckingham
- Moin Saleem Founder & CSA, Purespring Therapeutics
- Mustafa Munye VP Operations, Complement Therapeutics
- Nicola Bradley Senior Medicines Advice Pharmacist – Horizon scann, NHS SPS Medicines Advice & Horizon Scanning Service
- Nicola Robertson Professor of PerinatalProfessor of Perinatal Neuroscience & Consultant in NeonatologyNeuroscience, UCL
- Omer Dushek Professor of Molecular Immunology, University of Oxford
- Pamela Tranter Head, Translational Research Group (TRO), University College London
- Paul Gissen Clinical Professor of Paediatric Metabolic Medicine, UCL Great Ormond Street Institute of Child Health
- Rob Meijer Chief Executive Officer, Amphera
- Robert Henderson Honorary Associate Professor, UCL GOS Institute of Child Health
- Robert Wynn Consultant Paediatric Haematologist & Director of Paediatric Bone Marrow Transplant Programme, Manchester University NHS Foundation Trust
- Samantha Thomas Head of Research, ReNeuron
- Sheba Jarvis Consultant Endocrinology, Imperial College London
- Sheena Vithlani Medicines Advice Advanced Pharmacist, NHS SPS Medicines Advice & Horizon Scanning Service
- Sophia N Karagiannis Professor of Translational Cancer Immunology and Immunotherapy, King's College London
- Sophie Blondel Co-founder & CEO, Foxbio
- Tanya Patel Senior Manager CTSM, BioNTech
- Tina Karapouliou Research Fellow, UCL GOS ICH
- Tom Payne Chief Operating Officer, Laverock Therapeutics
- Azadeh Kia VP Gene Therapy Research, Beacon Therapeutics
- Bastiaan Leewis SVP MSAT, MeiraGTx
- Cecile Bauche CSO, Alaya.bio
- David Uguen SVP, Head of Regulatory Affairs, Orchard therapeutics
- Eleuterio Lombardo Former Director of Cell Therapy Characterization & Development, Cell Therapies, Takeda
- Florence Salmon Global Head Regulatory Cell and Gene Therapies, Roche
- Giovanni Rizzo Partner Biotech Fund, Indaco Venture Partners
- Ketki Vispute Associate Director, CMC, MSAT, Autolus Ltd
- Luke Henry Chief Business Officer, Quell Therapeutics
- Mary Wang Director, Patient Engagement, Genespire
- Matthieu Coutet Partner, Sofinnova Partners
- Robert Balfour Investment Director, Alsa Ventures
- Roberto Nitsch Director, AstraZeneca
- Roger Legtenberg Co-Founder & Managing Partner, Partners4Patients Foundation
- Sander Van Deventer Operating Partner, Forbion Capital Partners
- Sarah Snykers Head of Site Strategy and Excellence, Legend Biotech
- Sean Russell Head of Regulatory Affairs, Telethon Foundation
- Silvia Martin Lluesma Co-director of Advanced Cell Therapies Program, VHIO
- Steven Highfill Director of Product Development, Center for Cellular Engineering, Clinical Center, National Institutes of Health
- Noor Mujahid Head of Vector Process Development, NHS Centre for Cell Gene and Tissue Therapeutics
- Sara Aguti Senior Research Fellow, University College London
Agenda
Showing 80 of 260 sessions.
- Welcome Remarks 9 March 2027 · Keynote Theatre
- Chair’s Opening Remarks 9 March 2027 · Keynote Theatre
- Fireside Chat: Pioneering a new approach to advanced therapies - Establishing a not-for-profit model for developing a gene therapy 9 March 2027 · Keynote Theatre
- Keynote Panel Discussion: From Discovery to Manufacturing – How is AI Transforming Cell & Gene Therapy Development? 9 March 2027 · Keynote Theatre
- Chair’s Remarks: Dimitri Kullmann, Professor of Neurology, UCL Queen Square Institute of Neurology 9 March 2027
- Chair’s Remarks: Carolina Pola, CEO, STAb Therapeutics 9 March 2027
- Chair’s Remarks: Gaik Sui Kee, Director, Vector Development, Orchard Therapeutics 9 March 2027
- Chair’s Remarks: Nicola Redfern, Director, NJ Redfern Ltd. 9 March 2027
- Chair’s Remarks: James Levine, President, Fondation Ipsen, Ipsen 9 March 2027
- Chair’s Remarks: Diana Hernandez, Director of Immune and Advanced Therapies, Anthony Nolan 9 March 2027
- Chair's Remarks: David Morrow, Scientific Lead for Advanced Therapies, EATRIS 9 March 2027
- Chair’s Remarks: Jorg Wischhusen, Professor of Experimental Tumor Immunology, University of Wurzburg School of Medicine 9 March 2027
- Chair’s Remarks: Aline Charpentier, Science Strategy and Innovation Lead, Wellcome Genome Campus 9 March 2027
- Chair’s Remarks: Lara Campana, SVP, Research and Translational Science, Resolution Therapeutics 9 March 2027
- Insight from the NHS on apheresis and donor supply: Getting treatments to the patient 9 March 2027
- Exploring the differences between extrapolation and real-world outcomes 9 March 2027
- Are we ready for the age of biotech? 9 March 2027
- Robust manufacturing for replacement cell therapies 9 March 2027
- Preparing academic projects for commercialisation 9 March 2027
- Latest innovations in vector development manufacturing 9 March 2027
- Targeting and exploiting onco-fetal tolerance mechanisms for cancer and autoimmunity 9 March 2027
- Real world challenges of delivering CAR-T: Harsh realities and future perspectives 9 March 2027
- Developing gene therapy for common forms of epilepsy 9 March 2027
- Developing biological reference materials for the cell therapy field 9 March 2027
- Ex US optionality with an FDA approval: Go/ No go 9 March 2027
- Overview of MHRA's Innovation Accelerator for Innovative Products 9 March 2027
- Strategic considerations for designing supply networks for biologics and new modalities 9 March 2027
- National academic network proposal for authorization of CAR-T cell production 9 March 2027
- Latest insight on EU policies for ATMP development 9 March 2027
- Navigating Cell Therapy Manufacturing: Overcoming Bottlenecks and Creating a Capital-Efficient Path to Scale 9 March 2027
- Accelerated downstream process development for viral vectors 9 March 2027
- Extra corporeal CAR T for safe and accurate dosing 9 March 2027
- AI-powered approach to novel gene therapies 9 March 2027
- The good, bad and the ugly of venture creation 9 March 2027
- Stem cell gene therapy for childhood dementias 9 March 2027
- Dual CAR Targeting with CD33 and Tim3 in acute myeloid leukemia 9 March 2027
- Leveraging patient experience data to improve outcomes 9 March 2027
- Roundtable 11: How do we make novel therapies affordable for healthcare systems? 9 March 2027 · Keynote Theatre
- Roundtable 6: Designing ATMP processes with the end in mind - What should we fix early and what should we leave flexible? 9 March 2027 · Keynote Theatre
- Roundtable 5: Future-proofing cell therapies: Strategic lifecycle and comparability planning 9 March 2027 · Keynote Theatre
- Roundtable 9: LVV vs AAV: Key considerations on which approach to take? 9 March 2027 · Keynote Theatre
- Roundtable 14: Exploring the regulatory challenges for in vivo gene therapies 9 March 2027 · Keynote Theatre
- Roundtable 12: Commercial ATMP initiatives vs point of care initiatives 9 March 2027 · Keynote Theatre
- Roundtable 8: Exploring the safety considerations of CRISPR technology and different approaches to epigenetic editing 9 March 2027 · Keynote Theatre
- Roundtable 3: Workforce readiness to support delivery of ATMPs within the NHS 9 March 2027 · Keynote Theatre
- Roundtable 13: Future-proofing ATMPs: Navigating the regulatory minefield 9 March 2027 · Keynote Theatre
- Roundtable 10: Pros and cons of setting-up a clinical trial in the UK, Australia and South Korea 9 March 2027 · Keynote Theatre
- Roundtable 4: Harmonising safety standards for stem cell-based therapies 9 March 2027 · Keynote Theatre
- Roundtable 2: Tech Transfer from AD to QC: Overcoming pain points and hurdles 9 March 2027 · Keynote Theatre
- Roundtable 7: Exploring board-room effectiveness in biotech 9 March 2027 · Keynote Theatre
- Chair’s Remarks: Leila Abbas, Preclinical Lead, Rinri Therapeutics 9 March 2027
- Chair’s Remarks: Pilar Redondo, Site Head Madrid, Cell Therapy Technology Center, Takeda 9 March 2027
- Chair’s Remarks: Raphaël G. Ognar, CEO & Co-Founder, NKILT Therapeutics Inc 9 March 2027
- Chair’s Remarks: Patrick Hopkinson, Independent HTA Expert 9 March 2027
- Chair’s Remarks: Arsalan Wafi, Academic Clinical Lecturer, King's College London 9 March 2027
- Chair’s Remarks: Jaap Boelens, Chief Stem Cell Transplantation & Cellular Therapies Pediatrics, Memorial Sloan Kettering Cancer Center 9 March 2027
- Chair’s Remarks: Mohamed Awwad, Group Leader, Heidelberg University Hospital 9 March 2027
- Chair’s Remarks: Nicola Ambler, Co-Founder, The CGT Circle 9 March 2027
- Chair’s Remarks: Simon Howell, Professor, KCL 9 March 2027
- Chair's Remarks: Christian Hill, Board Member, European Confederation of Pharmaceutical Entrepreneurs 9 March 2027
- Supporting commercialisation through operational and supply chain strategies 9 March 2027
- Solving the EV Consistency Challenge: Enabling mass adoption through a platform approach 9 March 2027
- Engineering the biology of AAV secretion with MAAP 9 March 2027
- Unlocking the potential of disease prevention through regulatory science 9 March 2027
- Cell therapy for neonatal brain injury 9 March 2027
- The case for launching advanced therapies in RoW markets: Exploring challenges and opportunities 9 March 2027
- Breaking new barriers in neuroscience: Translational gene therapy for prevalent indications 9 March 2027
- Building an inclusive culture in biotech 9 March 2027
- Igniting childhood cancer gene therapy: Delivering impact for children 9 March 2027
- First in human trial for solid tumour in India 9 March 2027
- Scalability connection between manufacturing and QC 9 March 2027
- A NICE Lesson from the Frontline of a Gene Therapy Evaluation 9 March 2027
- Multi-pathway armouring of CAR-T cells 9 March 2027
- Gene therapy for kidney disease 9 March 2027
- Pre-clinical development of a CD19 parallel CAR 9 March 2027
- Developing your QC strategy for early and late phase development 9 March 2027
- Challenges of manufacturing in an academic hospital 9 March 2027
- NK-derived vesicles for cancer therapy 9 March 2027
- Operational considerations for the delivery of CAR-T 9 March 2027
- Lessons learned from spinning out in gene therapy 9 March 2027